Curi Bio Acquires Cartox™ Technology From Stembiosys, Announces Launch Of Nautilus™ Optical Mapping System

Mar 29, 2022•over 3 years ago

Acquiring Company

Curi Bio

Acquired Company

CarTox

SeattleScience And EngineeringSportsHealth CareBiotechnologyData And Analytics

Description

Curi Bio, a leading developer of human stem cell-based platforms and technologies for drug discovery, today announced the exclusive commercial acquisition from StemBioSys of the CarToxTM technology platform for calcium and voltage optical mapping. In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the NautilusTM optical mapping system. By providing drug developers with human-relevant tissue-specific biosystems in the preclinical stage of drug development, Curi helps pharmaceutical partners develop safer, more effective therapeutics.

Company Information

Company

Curi Bio

Location

Seattle, Washington, United States

About

Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. The company’s proprietary technologies are supported by over 100 publications and 19 patents. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines. For more information, please visit www.curibio.com.

DealWatch™ Score

High M&A Activity

M&A Opportunity Analysis

Get personalized insights on M&A opportunities

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor